News & Updates

Neoadjuvant–adjuvant bests adjuvant-only pembrolizumab in advanced melanoma
Neoadjuvant–adjuvant bests adjuvant-only pembrolizumab in advanced melanoma
14 Mar 2023

For patients with stage III or IV melanoma, treatment with pembrolizumab both before and after surgical resection leads to longer event-free survival than treatment with pembrolizumab only after the procedure, according to the results of a phase II study.

Neoadjuvant–adjuvant bests adjuvant-only pembrolizumab in advanced melanoma
14 Mar 2023
What are the signs of HSV infection in patients with pemphigus vulgaris?
What are the signs of HSV infection in patients with pemphigus vulgaris?
13 Mar 2023

Clinicians must be aware of the likelihood of infection with herpes simplex virus (HSV) in the presence of fissures, haemorrhagic crusts, linear erosions, erosions with angulated margins, and increased erythrocyte sedimentation rate among patients with pemphigus vulgaris, suggests a study.

What are the signs of HSV infection in patients with pemphigus vulgaris?
13 Mar 2023
Smoking cessation, preventing obesity help reduce psoriasis risk
Smoking cessation, preventing obesity help reduce psoriasis risk
11 Mar 2023

The incidence of psoriasis may be decreased by maintaining a normal weight and by putting a stop to the use of tobacco and cigarettes, a recent study has shown. In addition, addressing the inequality in education may help lower the cases of this condition.

Smoking cessation, preventing obesity help reduce psoriasis risk
11 Mar 2023
Dupilumab yields rapid, lasting improvement in erythrodermic atopic dermatitis
Dupilumab yields rapid, lasting improvement in erythrodermic atopic dermatitis
04 Feb 2023

Treatment with dupilumab helps improve the signs and symptoms of erythrodermic atopic dermatitis, with the improvements occurring as early as the first week and being sustained over time, according to a study. The drug has an acceptable safety profile.

Dupilumab yields rapid, lasting improvement in erythrodermic atopic dermatitis
04 Feb 2023
Oral ritlecitinib safe, effective for treatment of active nonsegmental vitiligo
Oral ritlecitinib safe, effective for treatment of active nonsegmental vitiligo
27 Jan 2023
Multiple moles, genetic predisposition up risk of second primary melanomas
Multiple moles, genetic predisposition up risk of second primary melanomas
22 Jan 2023